Jannah Theme License is not validated, Go to the theme options page to validate the license, You need a single license for each domain name.

3 stocks with 1,000% upside potential

If you are a risk taker looking for stocks with 1000% upside potential, you will need to venture into speculative territory. It’s hard to find analyst ratings with such high upside potential unless catalysts can propel the stock so high. These catalysts include promising drug candidates awaiting approval or in clinical trials. These catalysts may or may not materialize for years. If said company disappoints by losing the drug or failing to gain approval, shareholders will suffer substantial losses almost overnight.

Also, I won’t go into their finances too much. The only companies with such high growth potential are early-stage biotech startups that generate negligible revenue. Instead, focusing on drugs and their viability will give us a much better idea of ​​the future of the business.

With that in mind, let’s look at three stocks with 1,000% upside potential.

Aptosis Biosciences (APTO)

Source: Shutterstock

Aptosis Biosciences (NASDAQ:APTO) is a clinical-stage biotechnology company focused on developing personalized therapies for “hemal malignancies, such as acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL)” . The company has two blockbuster drugs: tuspetinib, a myeloid kinase inhibitor, and luxeptinib, a dual lymphoid and myeloid kinase inhibitor.

According to analysts, Aptose Biosciences has a $7 price target, representing a whopping 1,409% upside from its current price of $0.46. The company recently reported positive results of its Phase 1/2 trial of tuspetinib in patients with relapsed or refractory AML, showing clinical responses at four dose levels. The company has also launched the recruitment of a treatment arm combined with venetoclax, a reference treatment for AML.

Aptose Biosciences’ main catalyst is the progress of its clinical trials. It also has the potential to secure regulatory approvals and partnerships for its drug candidates. The company has a strong intellectual property portfolio and a strong portfolio of preclinical compounds. The company also has a cash trail of about a year. But again, I believe the promising drug candidates here mean fundraising shouldn’t be very complicated.

I think Aptose Biosciences is an undervalued gem in the biotech industry. It has a unique approach to target several kinases involved in cancer cell survival and proliferation. I believe it could end up being one of the stocks with 1000% upside. The company has demonstrated proof of concept for its lead drug candidates and has the potential to address significant unmet medical needs in hematological malignancies. But of course, start-up biotech companies come with a lot of risks. I wouldn’t rely solely on upside potential to make a decision whether or not to buy these stocks.

Checkpoint Therapeutics (CKPT)

A variety of pills, pill bottles and droppers arranged on a table in several bright colors.

Source: Shutterstock

Therapeutic checkpoint (NASDAQ:CKPT) is a clinical-stage biotechnology company developing drugs for various types of cancer. The company’s lead product candidate is cosibelimab, an antibody that targets ‘programmed death ligand-1 (PD-L1)’, a key regulator of the immune system.

The company recently announcement that the FDA has accepted the filing of its “Biologics License Application (BLA) for cosibelimab in patients with metastatic or locally advanced cutaneous squamous cell carcinoma (SCCC)”, a common and aggressive type of skin cancer. The FDA granted priority review to cosibelimab and set a PDUFA target date of January 3, 2024.

The primary catalyst for Checkpoint Therapeutics is the potential approval and launch of cosibelimab in the CSCC market. It is estimated at worth over $10 billion globally in 2020. Naturally, analysts have a $35 price target for Checkpoint Therapeutics. This implies a staggering 1175% upside, making it an easy choice for a stock story with a 1000% upside.

Achilles Therapeutics (ACHL)

Brown glass pill bottle on the side showing white pills inside, with other pill bottles behind representing MACK stock.

Source: shutterstock.com/Champei

Therapeutic Achilles (NASDAQ:ACHL) is a clinical-stage biotechnology company developing “personalized T-cell therapies targeting clonal neoantigens, which are protein markers unique to each individual and expressed on the surface of each cancer cell”.

The company uses its AI platform, PELEUS, to identify these neoantigens from DNA sequencing data. It uses the VELOS manufacturing process to create “clonal patient-specific neoantigen reactive T cell products” or cNeTs.

Analysts have $11 price target for Achilles Therapeutics, which implies an increase of 1,059%. There hasn’t been a lot of recent news, but the company reported positive data from its phase 1/2a trial last year. The trials showed that in patients with advanced non-small cell lung cancer (NSCLC) and melanoma, cNeTs showed tumor regression and durable responses.

I think regulatory approval is likely for cNeTs in the future. The company has a pragmatic approach to targeting clonal neo-antigens, present in all cancer cells and absent from normal cells. There is no single treatment that works for all cancers, but cNeTs certainly show promise because of this fact. They can likely treat a range of cancers, which could make ACHL one of the stocks with a 1000% upside.

At the date of publication, Omor Ibne Ehsan did not hold (neither directly nor indirectly) any position in the securities mentioned in this article. The opinions expressed in this article are those of the author, subject to InvestorPlace.com publishing guidelines.

Omor Ibne Ehsan is a writer at InvestorPlace. He is a self-taught investor who focuses on growth and cyclical stocks that have strong fundamentals and long-term potential. He is also interested in high-risk, high-reward investments such as cryptocurrencies and penny stocks. You can follow him on LinkedIn.


Not all news on the site expresses the point of view of the site, but we transmit this news automatically and translate it through programmatic technology on the site and not from a human editor.
Back to top button